Research

In America today, the elderly report less pain than those in midlife. This is the mystery of American pain.

Policies to address surprise billing could reduce health insurance premiums by 1% to 5%.

we study individual’s perceptions on COVID-19 and social distancing during the week of March 10–16, 2020, a week when COVID-19 was officially declared to be a pandemic by WHO and when new infections in the US were more than doubling every three days.

Scholars from the USC-Brookings Schaeffer Initiative for Health Policy Georgia’s latest 1332 Proposal, analyzing its major analytical errors and procedural deficiencies that render it unapprovable.

A mandatory business closure over three months results in a 20.3% decline of U.S. GDP on an annual basis, or $4.3 trillion, and an employment decline of 22.4%, representing 35.3 million workers.

This analysis highlights that most cost-utility analyses that cite high cost-effectiveness thresholds also result in greater incremental cost-effectiveness ratios for the novel interventions that they investigate.

Blood‐based biomarker tests are a promising tool to improve triaging Alzheimer’s disease at the primary care level.

This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.

Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.

This perspective in the American Journal of Kidney Diseases examines how the “Advancing American Kidney Health” Executive Order (AAKH) might reshape the US dialysis market.